Related by context. All words. (Click for frequent words.) 69 Gleevec resistant 69 relapsed leukemia 69 recurrent glioblastoma multiforme 69 kidney urologic 68 CYT# potent vascular disrupting 68 relapsed MM 68 OHR/AVR# 68 Cloretazine 68 relapsed multiple myeloma 68 Acute myeloid leukemia 67 allogeneic HSCT 67 multiple myeloma MM 67 Alemtuzumab 67 smoldering myeloma 67 rheumatologic 67 commercialize deforolimus 67 Ribavirin causes 66 metastatic kidney 66 Myelodysplastic Syndrome MDS 66 Daclizumab 66 Chronic lymphocytic leukemia CLL 66 metastatic gastric 66 TTR amyloidosis 66 leukemia AML 66 Chronic lymphocytic leukemia 66 relapsing remitting MS RRMS 66 Zolinza 66 relapsed ALL 66 diabetic kidney 66 Dacogen decitabine 66 adult chronic ITP 66 vWD 66 metastatic renal cell 66 OMP #R# 66 chemotherapeutic regimen 65 hypereosinophilic syndrome 65 myelodysplastic myeloproliferative diseases 65 LHRH antagonists 65 haematological malignancies 65 acute leukemias 65 allogeneic bone marrow 65 lumiliximab 65 metastatic malignant melanoma 65 galiximab 65 Teriflunomide 65 refractory Hodgkin 65 myelodysplastic syndrome MDS 65 Evoltra ® 65 invasive candidiasis 65 imatinib Gleevec ® 65 SNT-MC#/idebenone 65 gefitinib Iressa 65 Genentech Rituxan 65 smoldering multiple myeloma 65 GRN# 65 gastrointestinal stromal tumor GIST 65 Nexavar sorafenib 65 oral antiviral 65 systemic fungal infections 65 Ceflatonin 65 Gleevec imatinib mesylate 65 Annamycin 65 recurrent glioblastoma multiforme GBM 65 Naive Patients 65 refractory chronic lymphocytic 65 Omacetaxine 65 IAP inhibitor 65 metastatic bladder 65 Hepatocellular Carcinoma HCC 65 EGFR inhibitors 65 GW# [003] 65 Glioblastoma Multiforme 65 alvespimycin 64 advanced metastatic renal 64 neovascular diseases 64 Talotrexin 64 oxypurinol 64 T#I [002] 64 multivessel coronary artery 64 candidemia 64 BRAF inhibitor 64 Cell Lymphoma CTCL 64 tumors GIST 64 AA Amyloidosis 64 LymphoStat B belimumab 64 receptor tyrosine kinase inhibitor 64 erlotinib Tarceva ® 64 Gleevec imatinib 64 nonsmall cell lung cancer 64 malignant pleural mesothelioma 64 HIV coinfected 64 Xanafide 64 psoriasis rheumatoid arthritis 64 Acute Myelogenous Leukemia AML 64 treating neuropathic pain 64 Relapsing remitting MS 64 constipation OIC 64 sunitinib malate 64 Ceflatonin R 64 refractory indolent non 64 myelofibrosis polycythemia vera 64 relapsing multiple sclerosis 64 Myelodysplastic syndromes 64 reslizumab 64 mycosis fungoides 64 thalidomide Thalomid 64 Aflibercept 64 thetreatment 64 PLX MS 64 Rituxan rituximab 64 Glioblastoma multiforme GBM 64 Velcade bortezomib 64 sorafenib Nexavar ® 64 atypical hemolytic uremic syndrome 64 indolent NHL 64 pediatric acute lymphoblastic 64 AEG# 64 Biogen Avonex 64 Virulizin ® 64 HER2 overexpression 64 gastrointestinal stromal tumors GIST 64 Atypical Hemolytic Uremic Syndrome 64 anthracycline taxane 64 homozygous familial hypercholesterolemia 64 allogeneic hematopoietic stem cell 64 hepatitis C HCV 64 Phase Ib IIa 64 paroxysmal nocturnal hemoglobinuria 64 Fludarabine 64 anticancer therapies 63 chronic eosinophilic leukemia 63 antiangiogenic agent 63 pulmonary hypertension PH 63 haematological cancers 63 dirucotide MBP# 63 including eniluracil ADH 63 Cinquil 63 HIV HCV coinfected 63 de novo kidney transplant 63 imatinib resistant 63 Vidaza azacitidine 63 signal transduction inhibitors 63 sorafenib tablets 63 myeloproliferative 63 Voreloxin 63 secondary hyperparathyroidism 63 non hodgkin lymphoma 63 vemurafenib 63 chronic myocardial ischemia 63 haematopoietic stem cell 63 Alessandro Riva 63 HBeAg negative 63 Surgical resection 63 Waldenstrom macroglobulinemia 63 riociguat 63 invasive aspergillosis 63 basiliximab 63 myeloproliferative neoplasms 63 TTF Therapy 63 humanised monoclonal antibody 63 leukemia CLL 63 pancreatic NET 63 transplantation HCT 63 idiopathic pulmonary fibrosis IPF 63 Blinatumomab 63 Sudhir Agrawal D.Phil 63 RhuDex R 63 investigational monoclonal antibody 63 HuLuc# 63 dasatinib Sprycel ® 63 OncoVex 63 Vidaza ® 63 MELAS 63 hormone refractory 63 vinca alkaloid 63 IMA# 63 Mipomersen 63 Cutaneous T 63 Symadex 63 pertuzumab 63 decompensated liver disease 63 anti angiogenic agents 63 PDE# inhibitors 63 neuroendocrine cancers 63 BARACLUDE ® 63 Investigational Treatment 63 metaglidasen 63 echinocandin 63 myelogenous leukemia 63 evaluating tivozanib 63 multi kinase inhibitor 63 hepatitis C genotype 63 malignant lymphomas 63 radiation sensitizer 63 hematologic disorders 63 MAGE A3 ASCI 63 CCR5 receptor antagonist 63 elacytarabine 63 Epratuzumab 63 acyclovir Lauriad R 63 pancreatic carcinoma 63 malignant ascites 63 Myelodysplastic Syndrome 63 JAK inhibitor 63 PD LID 63 CMV infections 63 pemphigus vulgaris 63 tigecycline 63 alefacept 63 Myelodysplastic syndromes MDS 63 either acutely decompensated 63 Zenapax 63 polycythemia vera essential thrombocythemia 63 bendamustine 63 MKC# MT 63 bortezomib Velcade R 63 herpetic keratitis 63 visilizumab 63 Cariprazine 63 dasatinib Sprycel 63 immunodeficiency disorders 63 anti angiogenic therapy 63 non alcoholic steatohepatitis 63 recurrent genital herpes 63 K ras mutations 63 Non Hodgkins lymphoma 63 Heterozygous Familial Hypercholesterolemia 63 IV Busulfex 63 AGILECT R 63 refractory CLL 63 metastatic colorectal 63 Deforolimus 63 rituximab Rituxan 63 alemtuzumab Campath 63 squamous cell lung cancer 63 Olaparib 63 histologic subtype 63 Temsirolimus 63 Tykerb lapatinib 63 CMV retinitis 63 VEGF inhibitors 63 Elacytarabine 63 Pulmonary hypertension 63 Lenalidomide 63 IMiDs 62 MabThera Rituxan 62 metastatic renal 62 Novartis Gleevec 62 esophageal candidiasis 62 R sorafenib tablets 62 ATTR PN 62 Liprotamase 62 Crizotinib 62 Systemic lupus erythematosus SLE 62 YONDELIS 62 Campath ® 62 Anti VEGF 62 relapsed AML 62 Gemzar gemcitabine 62 flavopiridol 62 Renal Cell Carcinoma RCC 62 Revlimid lenalidomide 62 refractory colorectal cancer 62 therapeutic regimens 62 genetic lysosomal storage 62 Pertuzumab 62 targeted radiotherapeutic 62 lenalidomide Revlimid 62 myelodysplastic syndromes 62 hematological cancers 62 muscular dystrophy cystic fibrosis 62 virally induced 62 cutaneous T 62 relapsed refractory AML 62 Campath alemtuzumab 62 ZOLINZA 62 pediatric Crohn disease 62 castrate resistant 62 Roche Xeloda 62 ZACTIMA TM ZD# 62 leukemia ALL 62 Glioblastoma multiforme 62 papillary renal cell carcinoma 62 noscapine 62 previously untreated follicular 62 alpha folate receptor 62 acute GvHD 62 antiretroviral naïve 62 taxane chemotherapy 62 bevacizumab Avastin ® 62 invasive fungal infections 62 Malignant glioma 62 relapsed SCLC 62 juvenile idiopathic arthritis JIA 62 lysosomal storage disease 62 recurrent glioblastoma 62 Arranon 62 steroid refractory 62 MGd 62 efalizumab 62 Azedra 62 leukemia APL 62 erlotinib Tarceva 62 systemic ALCL 62 Amgen Neulasta R 62 davunetide intranasal AL 62 GRNOPC1 contains 62 TroVax ® 62 rALLy clinical trial 62 Hodgkin lymphoma HL 62 investigational therapies 62 Degarelix 62 Bayer HealthCare Onyx Pharmaceuticals 62 hepatorenal syndrome 62 anthracycline chemotherapy 62 Acute Myelogenous Leukemia 62 Panzem R NCD 62 progressive neurodegenerative disorder 62 eosinophilic asthma 62 therapeutic monoclonal antibody 62 corticosteroid dexamethasone 62 diabetic neuropathic pain 62 basal cell carcinoma BCC 62 cyclophilin inhibitors 62 monoclonal antibody therapeutics 62 regorafenib 62 schizophrenia CIAS 62 SJIA 62 LymphoStat B TM 62 advanced medullary thyroid 62 CTAP# Capsules 62 glioblastoma multiforme GBM 62 Lung transplantation 62 TKI therapy 62 refractory NSCLC 62 essential thrombocythemia ET 62 Anthracycline 62 forodesine 62 rufinamide 62 non metastatic osteosarcoma 62 Pseudomonas aeruginosa infections 62 CINQUIL 62 Tyrosine Kinase Inhibitors 62 Chronic Myeloid Leukemia 62 metastatic hormone refractory 62 Hepsera adefovir dipivoxil 62 RhuDex ® 62 alkylating agent 62 Myelodysplastic syndrome 62 Aviptadil 62 cytomegalovirus retinitis 62 psoriasis Crohn disease 62 mRCC 62 chronic myeloid 62 antibody mediated 62 DEB# 62 rALLy 62 Eraxis 62 anticancer therapy 62 Hodgkin lymphoma NHL 62 toenail onychomycosis 62 cisplatin chemotherapy 62 primary immunodeficiency PI 62 thalassemia sickle cell 62 chronic GVHD 62 apricitabine 62 Fibrillex TM 62 superficial bladder cancer 62 protein kinase inhibitor 62 noninfectious uveitis 62 Vandetanib 62 Juvenile Idiopathic Arthritis JIA 62 differentiated thyroid 62 Belimumab 62 Hereditary angioedema HAE 62 pancreatic adenocarcinoma 62 immunomodulatory therapy 62 biliary tract cancer 62 Gleevac 62 cell lymphoma CTCL 62 acute myelogenous leukemia AML 62 antimetabolite 62 systemic mastocytosis 62 Idiopathic pulmonary fibrosis 61 stage IIIB IV 61 Lupus nephritis 61 unresectable tumors 61 endocrine therapies 61 biologic DMARD 61 EndoTAGTM 1 61 advanced metastatic prostate 61 Pulmonary arterial hypertension 61 interferon beta therapy 61 TBC# 61 Nilotinib 61 autoantibody positive 61 CDP# 61 Arzerra ofatumumab 61 Relapsed Refractory 61 null responder HCV 61 angiogenesis inhibition 61 boosted protease inhibitor 61 Stargardt Macular Dystrophy SMD 61 Panzem 61 Elotuzumab 61 Rasagiline 61 herpes zoster shingles 61 tipranavir ritonavir 61 acute promyelocytic leukemia APL 61 Acute Coronary Syndromes ACS 61 cirrhosis liver failure 61 lupus nephritis 61 Fabry Disease 61 acute coronary syndromes ACS 61 heavily pretreated 61 metastatic neuroendocrine tumors 61 lenalidomide Revlimid R 61 ospemifene 61 Bcr Abl mutations 61 psoriasis psoriatic arthritis 61 Onco TCS 61 Pyridorin 61 demethylating agent 61 serologically active systemic lupus 61 miglustat 61 Noxafil 61 Romidepsin 61 adalimumab Humira 61 Acute myeloid leukemia AML 61 elvucitabine 61 phase IIb clinical 61 lupus multiple sclerosis 61 debilitating complication 61 peritumoral brain edema 61 trastuzumab Herceptin ® 61 Acute Myeloid Leukemia AML 61 relapsed ovarian cancer 61 cyclophosphamide chemotherapy 61 Archexin 61 Dasatinib 61 Nexavar ® 61 inherited neurodegenerative disorder 61 metastatic malignant 61 mapatumumab 61 PNP inhibitor 61 PROCHYMAL 61 protein kinase inhibitors 61 imatinib Gleevec 61 LHON 61 systemic autoimmune 61 rheumatoid arthritis psoriatic arthritis 61 skeletal metastases 61 Cell Non Hodgkin 61 refractory metastatic 61 tyrosine kinase inhibitors TKIs 61 ZACTIMA 61 IGF 1R inhibitor 61 cardio renal 61 Etanercept 61 TNF antagonist therapy 61 common hematologic malignancy 61 virotherapy 61 CMV vaccine 61 C1 INH deficiency 61 proteasome inhibitor 61 Dacogen injection 61 calcineurin inhibitor 61 refractory gout 61 SSc 61 de novo AML 61 M2 subunit 61 Pfizer Camptosar 61 solid organ transplantation 61 heterozygous FH 61 tumor subtypes 61 TNF alpha inhibitor 61 histologies 61 mTOR inhibitor 61 Pamidronate 61 dexpramipexole 61 Behcet uveitis 61 paclitaxel Taxol ® 61 Avonex interferon beta 1a 61 cMET 61 Mitoxantrone 61 lapatinib Tykerb 61 Adjuvant chemotherapy 61 recurrent NSCLC 61 Azacitidine 61 BENLYSTA TM 61 Cabazitaxel 61 ELACYT 61 TNF alpha inhibitors 61 RNAi therapeutic targeting 61 IMiDs ® compound 61 FOLFOX chemotherapy 61 eflornithine 61 IMiDs R 61 Chronic myeloid leukemia CML 61 Acute myelogenous leukemia 61 Amgen Neulasta ® 61 gastrointestinal stromal tumor 61 SNT MC# 61 nucleoside analog 61 leukemia multiple myeloma 61 Romiplostim 61 chronic idiopathic thrombocytopenic purpura 61 Eculizumab 61 Host Disease GvHD 61 indolent follicular non 61 protease inhibitor PI 61 vorinostat 61 Biogen Idec Avonex 61 Maribavir 61 BCR ABL inhibitor 61 imatinib resistance 61 Pegloticase 61 haematologic malignancies 61 FUSILEV enhances 61 AA amyloidosis 61 anthracyclines taxanes 61 lintuzumab SGN 61 retinal vein occlusion 61 aflibercept VEGF Trap 61 hematological diseases 61 CHOP chemotherapy 61 Idiopathic Pulmonary Fibrosis 61 Cimzia TM 61 refractory acute myeloid 61 psoriatic arthritis PsA 61 mutated KRAS gene 61 Temodar ® 61 IBS C 61 PLX STROKE targeting 61 opioid induced constipation OIC 61 endothelin receptor antagonists 61 myeloproliferative disorders 61 thiazolides 61 atypical Hemolytic Uremic Syndrome 61 portal vein thrombosis 61 nonmetastatic 61 NMIBC 61 HER2 positive metastatic breast 61 deletion 5q 61 daptomycin 61 Doxil ® 61 Troxatyl 61 Torisel 61 juvenile idiopathic arthritis 61 Arcalyst 61 Phase IIb clinical trials 61 samalizumab 61 gastrointestinal stromal tumors 61 Phase #b/#a clinical 61 Diamyd ® 61 chronic lymphocytic leukemia CLL 61 Neulasta R 61 Provectus Pharmaceuticals specializes 61 Sapacitabine 61 stage IIIb IV 61 docetaxel Taxotere R 61 Dalbavancin 61 complement inhibitor eculizumab 61 myeloproliferative neoplasms MPNs 61 Syndax Pharmaceuticals Inc. 61 Riluzole 61 Amrubicin 61 LHRH receptor positive 61 OMP #M# 61 SPRYCEL ® 61 OnDose TM 61 TMS Therapy 61 Alocrest 61 Cancidas 61 PSMA ADC 61 antibody MAb 61 tyrosine kinase inhibitor TKI 61 neurological manifestations 61 nucleoside analogues 61 Aplidin 61 Novartis Zometa 61 Gamunex C 61 RELOVAIR ™ 61 Cloretazine ® 61 LEUKINE 61 INS# [001] 61 ANCA associated 61 Epidermal Growth Factor Receptor 60 pediatric bipolar disorder 60 mecasermin 60 Lixivaptan 60 Vascugel 60 Certolizumab pegol 60 monoclonal antibody MAb 60 Glioblastoma Multiforme GBM 60 bortezomib Velcade 60 Peginterferon alfa 2b 60 azacitidine 60 Progressive Multifocal Leukoencephalopathy 60 HCV infection 60 TNF Tumor Necrosis Factor 60 novel VDA molecule 60 familial amyloidotic polyneuropathy FAP 60 Dementia Related Psychosis 60 calcineurin inhibitors 60 Ixempra 60 MabThera rituximab 60 metastatic HRPC 60 induced macular edema 60 direct thrombin inhibitors 60 metastatic renal cell carcinoma 60 lymphoid tumors 60 GVAX Pancreas Vaccine 60 cSSSIs 60 unresectable stage 60 BCR ABL inhibitors 60 Natalizumab 60 nonsquamous 60 vidofludimus 60 Friedreich Ataxia FRDA 60 Immunotherapeutic 60 sorafenib Nexavar 60 Pemetrexed 60 Factor VIIa 60 Panzem R 60 relapsed refractory multiple myeloma 60 hematopoietic cell 60 thrombocytopenic 60 advanced carcinoid 60 pharmacokinetic interactions 60 Acute Myeloid Leukaemia AML 60 PEG interferon 60 GI motility disorders 60 Azathioprine 60 Relapsed Refractory Multiple Myeloma 60 ImClone Erbitux 60 JAK inhibitors 60 Aliskiren 60 deCODE Glaucoma TM 60 Fludara ® 60 overt nephropathy 60 Leber Congenital Amaurosis LCA 60 hematopoietic cancers 60 ATG Fresenius S 60 leukemia lymphoma multiple myeloma 60 baminercept 60 essential thrombocythemia 60 nonalcoholic steatohepatitis NASH 60 MYLOTARG 60 Letairis ambrisentan 60 Testosterone deficiency 60 liposomal formulation 60 Leukemias 60 Tarceva TM 60 delta gamma agonist 60 Zometa zoledronic acid 60 idiopathic thrombocytopenic purpura ITP 60 Diffuse Large B 60 pan HDAC inhibitor 60 midstage clinical 60 HGS# 60 carcinoid 60 colorectal carcinoma 60 mTOR inhibitors 60 systemic amyloidosis 60 lymphocytic leukemia 60 myelodysplastic syndromes MDS 60 lung fibrosis 60 Onrigin 60 oxaliplatin Eloxatin 60 long acting bronchodilator 60 Sutent sunitinib 60 oncolytic vaccine 60 congenital hemophilia 60 immunosuppressed patients 60 nucleotide analogue 60 chronic rheumatic 60 nucleoside analogue 60 Follicular lymphoma 60 MGUS 60 Tarvacin 60 Metastatic breast cancer 60 gastrointestinal stromal tumors GISTs 60 Hurler syndrome 60 Chronic Lymphocytic Leukemia CLL 60 CytoFabTM 60 lomitapide 60 Isentress raltegravir 60 HCD# [002] 60 omacetaxine mepesuccinate 60 cilengitide 60 ATL/TV# 60 late onset Pompe 60 aMCI precursor 60 pegylated interferons 60 valganciclovir 60 Allovectin 7 ® 60 proliferative retinopathy 60 pediatric malignancies 60 Bevacizumab 60 bronchogenic carcinoma 60 ChronVac C R 60 ALN PCS 60 LHRH agonists 60 ToGA 60 inflammatory demyelinating 60 chronic thromboembolic pulmonary 60 dyskeratosis congenita 60 immunocompetent adults 60 zanolimumab 60 huN# DM1 60 cytomegalovirus infection 60 Lilly Alimta 60 taxane refractory 60 ara C 60 Squalamine 60 AVONEX ® 60 pancreatic neuroendocrine tumors 60 chimeric monoclonal antibody 60 patientswith 60 Tekamlo 60 gemcitabine Gemzar 60 Trastuzumab DM1 60 recurrent metastatic 60 non mutated KRAS 60 hormone LHRH antagonist 60 fallopian tube carcinoma 60 homozygous FH 60 Candida infection 60 molecularly targeted 60 recurrent metastatic ovarian cancer 60 ALN TTR 60 Sanofi Aventis Taxotere 60 Exelixis XL# 60 benign prostatic hypertrophy BPH 60 immunosuppressive therapies 60 acute promyelocytic leukemia 60 p# biomarker 60 recombinant hepatitis B 60 Phase #/#a trial 60 Mitomycin C 60 Talabostat 60 Myelofibrosis 60 retinal vein occlusion induced 60 Navelbine ® 60 gastrin analogue TT 60 systemic anaplastic large 60 pegylated interferon alpha 60 cytotoxics 60 NNRTIs 60 Soliris eculizumab 60 Acute Exacerbations 60 autoimmune uveitis 60 oral vancomycin 60 Onconase 60 Ranibizumab 60 posterior uveitis 60 immune thrombocytopenic purpura 60 EGFR mutation positive 60 hepatitis B HBV 60 resectable pancreatic cancer 60 Graft Versus Host 60 generation purine nucleoside 60 NS5b 60 systemic juvenile idiopathic 60 prostate cancer CaP 60 hypophosphatasia 60 epithelial tumors 60 BRAF V#E mutation 60 mitoxantrone plus 60 untreated multiple myeloma 60 Vicinium TM 60 metastatic colon cancer 60 Chronic Myelogenous Leukemia CML 60 Rilonacept 60 Fingolimod 60 IAP inhibitors 60 elotuzumab 60 Femara letrozole 60 Ridaforolimus 60 Xelox 60 induced anemia 60 terlipressin 60 adverse cytogenetics 60 medically inoperable 60 acute myeloid 60 relapsing remitting multiple sclerosis 60 Congenital Emphysema 60 cancer cachexia 60 Pneumocystis carinii pneumonia 60 farletuzumab 60 oral talactoferrin 60 MYCN amplification 60 HCV NS5B polymerase 60 OSUCCC James 60 Lupus Nephritis 60 TRAIL receptor antibodies 60 Myocet 60 lenalidomide dexamethasone 60 PF # [002] 60 type 1diabetes 60 phase IIb trial 60 ADPKD 60 Specifid 60 hereditary deficiency 60 AKT inhibitor 60 Tavocept 60 Lafora disease 60 Valvular heart 60 ABSSSI 60 TRIOLEX HE# APOPTONE HE# 60 solanezumab 60 follicular lymphomas 60 panobinostat 60 Bacillus Calmette Guerin BCG 60 CEQ# 60 Pazopanib 60 tyrosine kinase inhibitor 60 NASH Huntington 60 Leber congenital amaurosis LCA 60 OZURDEX ® 60 chronic ITP patients 60 CCR5 tropic 60 miconazole Lauriad ® 60 Sezary syndrome 60 ocular inflammatory 60 recurrent glioma 60 castrate resistant prostate cancer 60 Nanobody 60 predominantly classic subfoveal 60 HeFH 60 Telintra 60 severe malignant osteopetrosis 60 Pfizer Sutent 60 neovascular 60 fusion enhancers 60 induce remission 60 transthyretin amyloidosis 60 Gefitinib 60 multi infarct dementia 60 ocrelizumab 60 Rituximab 60 Acute Bacterial Sinusitis ABS 60 Cellcept 60 hypercholesterolemic patients 60 Chronic pancreatitis 60 ceftazidime 60 intravenous cyclophosphamide 60 debilitating autoimmune 60 subcutaneously administered 60 Gleevec Glivec 60 erythropoietic 60 chronic HBV 60 GSK '# 60 mutated KRAS 60 BrachySil TM 60 nonalcoholic steatohepatitis 60 Roche Actemra 60 gamma secretase inhibitor 60 myocardial infarction ventricular fibrillation 60 ® lenalidomide 60 interferon ribavirin 60 psoriasis inflammatory bowel 60 Adrenomyeloneuropathy AMN 60 BAY #-# 60 Herceptin trastuzumab 60 Tocilizumab 60 chronic HBV infection 60 myopic CNV 60 peritoneal carcinomatosis 60 dexanabinol 60 basal cell nevus syndrome 60 systemic lupus erythematosus 60 inhibit metastasis 60 Plicera 60 relapsed mantle 60 mCRPC 60 vosaroxin 60 null responder 60 hepatitis C viral infection 60 Enzastaurin 60 Paraplatin 60 deforolimus 60 Zemplar Capsules 60 evaluating REVLIMID 60 transplantation HSCT 60 SHPT 60 oral rivaroxaban 60 Vitaxin 60 docetaxel Taxotere ® 60 choroidal vasculopathy 60 APTIVUS R 60 Eisenmenger syndrome 60 ACTEMRA TM 59 Folfox 59 aflibercept 59 acetonide FA 59 JAK3 59 antithrombotic therapy 59 anagrelide 59 Neovascular AMD 59 diffuse gastric 59 Bortezomib 59 HQK 59 Tesmilifene 59 ruboxistaurin 59 novel therapeutic antibodies 59 microtubule inhibitor 59 Plaque psoriasis 59 Ocrelizumab 59 tocilizumab 59 postoperative ileus 59 Mepact 59 Severe Primary IGFD 59 Apaziquone 59 autologous transplants 59 Teva Copaxone 59 refractory chronic myeloid 59 mda 7 59 recurrent ovarian cancer 59 clobazam 59 allogeneic hematopoietic cell 59 molecularly targeted therapies 59 curative therapy 59 Umbilical cord stem cells 59 Removab 59 metastatic uveal melanoma 59 pegylated liposomal doxorubicin 59 ganetespib 59 EOquin TM 59 mycophenolate mofetil 59 ADP receptor antagonist 59 ENMD # 59 Prestara 59 advanced nonsquamous NSCLC 59 Clevudine 59 nephropathic cystinosis 59 nilotinib Tasigna ® 59 EGFr expressing metastatic colorectal 59 cabazitaxel 59 chemotherapy induced neutropenia 59 GEM OS2 59 familial hypercholesterolemia FH 59 Retigabine 59 diffuse intrinsic pontine glioma 59 metastatic sarcomas 59 XmAb# 59 tuberous sclerosis TS 59 ImmunoGen TAP technology 59 familial adenomatous polyposis FAP 59 metastatic carcinoid 59 INSPIRE Trial Phase III 59 Rilutek 59 #I TM# 59 HuMax CD4 59 rituximab Rituxan ® 59 FOLOTYN ® 59 Intravenous immunoglobulin 59 Personalized Immunotherapy 59 severe hypercholesterolemia 59 pharmacologic intervention 59 Li Fraumeni Syndrome 59 Incretin mimetics 59 VA# [002] 59 Nicole Onetto MD 59 SIR Spheres 59 xanthine oxidase inhibitor 59 alveolar rhabdomyosarcoma 59 tamoxifen Nolvadex ® 59 Host Disease 59 Fodosine 59 CTAP# 59 idarubicin 59 lymphoma leukemia 59 TNF alpha antagonist 59 angiotensin receptor blockers ARBs 59 Anaplastic 59 Allovectin 7 59 oropharyngeal candidiasis 59 anemias 59 radiochemotherapy 59 oral ridaforolimus 59 Autoimmune diseases 59 tafamidis 59 Non inferiority 59 Safinamide 59 gemcitabine carboplatin 59 Golimumab 59 Amgen Enbrel 59 combination antiretroviral therapy 59 carcinoid tumors 59 Cholangiocarcinoma 59 Zemplar 59 ketolide antibiotic 59 Lilly Gemzar 59 Proxinium TM 59 cyclophosphamide FC 59 PEGylated Fab fragment 59 RhuDex TM